Trial Profile
An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms EXPANDER-1
- 03 Jun 2020 Results of long-term outcomes from THINKER and EXPANDER trials, presented at the 2020 American Transplant Congress.
- 06 Mar 2018 Results assessing safety and efficacy of prophylaxis with direct acting antivirals before and after kidney transplantation from HCV-infected donors to non-HCV-infected recipients published in the Annals of Internal Medicine
- 05 Mar 2018 Status changed from active, no longer recruiting to completed.